source
- STAT+: Epic defends competitive practices; promises AI access to recordsIn this edition of STAT Health Tech: EHR giant, Epic defends its competitive tactics, new data on AI and health care costs, and HLTH news.STAT · 16h ago↗ source
- FDA approves Infilbray, first therapy for neurological symptoms of Type 3 Gaucher diseaseThe U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets for treating the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15…